| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
|
| ln Vitro |
Compound 6 (IRG1-IN-1; 0.5 mM; 2 mM) inhibits the release of TNFα and itaconic acid from human monocyte-derived macrophages (hMDMs) activated by lipopolysaccharide (LPS) [1]. C-IRG1-9 rat glioma cell growth is inhibited by IRG1-IN-1 (0.5 mM; 1 mM)[1]. TCR-activated hCD8+ T cell proliferation is enhanced by IRG1-IN-1 (10 nM)[1]. In CR-activated hCD8+ T cells, IRG1-IN-1(10μM) exhibits a reduction in the trimethylation of histone 3 at lysine 4 (H3K4me3)[1].
|
|---|---|
| ln Vivo |
In C57BL/6 mice, IRG1-IN-1 (compound 6) (ip; 0.2 mg/kg; 27 days) exhibits antitumor effect[1].
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: TCR-activated hCD8+ T cells Tested Concentrations: 10 μM Incubation Duration: 24-72 h Experimental Results: diminished protein levels of histone 3 (H3). Cell Proliferation Assay[1] Cell Types: C-IRG1-9 rat glioma cells and TCR-activated hCD8+ T cells Tested Concentrations: 0.5 mM; 1 mM; 10 nM Incubation Duration: 48- 96 h Experimental Results: Inhibited the proliferation of C-IRG1-9 rat glioma cells and increased proliferation of TCR-activated hCD8+ T cells. |
| Animal Protocol |
Animal/Disease Models: C57BL/6 mice[1]
Doses: 0.2 mg/kg Route of Administration: IP; 27 days Experimental Results: Increased survival of C57BL/6 mice bearing mouse CT26 colorectal tumors. diminished intratumoral frequency of M-MDSCs in tumors. |
| References |
[1]. Adonia Papathanassiu, et al. Compositions and methods of using itaconic acid derivatives. Patent. US20210261495A1.
|
| Molecular Formula |
C18H15FO4
|
|---|---|
| Molecular Weight |
314.31
|
| CAS # |
2407652-42-8
|
| Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
| SMILES |
C(O)(=O)C(=CC1=CC=C(F)C=C1)C(CC1=CC=CC=C1)C(O)=O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (318.16 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.95 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.95 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.95 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1816 mL | 15.9079 mL | 31.8157 mL | |
| 5 mM | 0.6363 mL | 3.1816 mL | 6.3631 mL | |
| 10 mM | 0.3182 mL | 1.5908 mL | 3.1816 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
